Institution
Saint Francis University
Education•Loretto, Pennsylvania, United States•
About: Saint Francis University is a education organization based out in Loretto, Pennsylvania, United States. It is known for research contribution in the topics: Population & Osteoblast. The organization has 1694 authors who have published 2038 publications receiving 87149 citations.
Topics: Population, Osteoblast, Growth factor, Bone cell, Bone remodeling
Papers published on a yearly basis
Papers
More filters
••
01 Jan 2022TL;DR: In this article, the basic concepts of pressure maintenance and active mechanisms during pressure maintenance in naturally fractured reservoirs are summarized and the essential concepts in simulation of pressure management in fractured reservoirs is provided.
Abstract: Gas injection into the gas cap which is known as pressure maintenance or crestal gas injection is done to increase the reservoir pressure. Different types of gas may be injected in this method including producing gas, N2, CO2 etc. The injected gas is chosen base on the field development studies. Each of these gases has some advantage and disadvantages. Gas injection in naturally fractured reservoirs is a challenge which needs more investigation on this subject. This chapter summarizes the basic concepts of pressure maintenance and active mechanisms during pressure maintenance in naturally fractured reservoirs. Also, this chapter provides the essential concepts in simulation of pressure maintenance in fractured reservoirs.
1 citations
••
TL;DR: Intravenous loop diuretics are the most commonly used medication for hospitalized congestive heart failure patients; however, many questions remain regarding their best use.
1 citations
••
1 citations
••
TL;DR: VB-111 was safe and well-tolerated alone and in combination with BEV in rGBM patients and was superior to the historical control BELOB BEV arm, 16 versus 8 months (p = 0.003).
Abstract: BACKGROUND: VB-111 is an anti-angiogenic agent consisting of a non-replicating adenovirus vector (Ad-5) with a modified murine pre-proendothelin promoter leading to apoptosis of tumor-vasculature by expressing a fas-chimera transgene in angiogenic-endothelial cells. Safety and efficacy of VB-111 alone and in combination with bevacizumab (BEV) were evaluated in recurrent-Glioblastoma (rGBM) patients in this Phase 1-2 dose-escalation study. METHODS: VB-111 was administered at 3x1012 or 1x1013 bimonthly until progression, followed by BEV standard-of-care (SOC). The protocol was amended to add-on BEV 10mg/Kg biweekly combined with VB-111 bimonthly, until further progression. Assessments included safety, pharmacokinetics, overall survival (OS) (Kaplan Meyer) and tumor response (RANO). RESULTS: 46 patients at 4 sites (US and Israel) received up to 13 doses of VB-111. Upon further progression, 24 received VB-111 with BEV, 22 were treated with BEV SOC. VB-111 was safe and well-tolerated alone and in combination with BEV. There were 30 grade ≥3 AEs, of which 6 were considered possibly related to VB-111: thrombocytopenia, pyrexia, brain edema, depressed consciousness, general weakness, pulmonary embolism. Median OS was 16 months for patients receiving combination therapy versus 8 months for those receiving SOC (p= 0.05). OS of combination therapy was superior to the historical control BELOB BEV arm, 16 versus 8 months (p = 0.003). Of 46 patients who received VB-111, 25 patients spiked a fever post-VB-111 dosing at least once, while 21 didn't. Feverish patients demonstrated a median OS of 16 months, compared to non-feverish patients, with a median OS of 8.5 months (p = 0.03). CONCLUSIONS: VB-111 was safe and well-tolerated alone and in combination with BEV in rGBM patients. OS of patients who received VB-111 followed by combination therapy almost doubled compared to historical BEV data, and compared to patients who received VB-111 monotherapy. Toxicities were as expected in this population. A phase 3 randomized controlled trial is currently underway.
1 citations
Authors
Showing all 1697 results
Name | H-index | Papers | Citations |
---|---|---|---|
Steven M. Greenberg | 105 | 488 | 44587 |
Linus Pauling | 100 | 536 | 63412 |
Ernesto Canalis | 98 | 331 | 30085 |
John S. Gottdiener | 94 | 316 | 49248 |
Dalane W. Kitzman | 93 | 474 | 36501 |
Joseph F. Polak | 91 | 406 | 38083 |
Charles A. Boucher | 90 | 549 | 31769 |
Lawrence G. Raisz | 82 | 315 | 26147 |
Julius M. Gardin | 76 | 253 | 38063 |
Jeffrey S. Hyams | 72 | 357 | 22166 |
James J. Vredenburgh | 65 | 280 | 18037 |
Michael Centrella | 62 | 120 | 11936 |
Nathaniel Reichek | 62 | 248 | 22847 |
Gerard P. Aurigemma | 59 | 212 | 17127 |
Thomas L. McCarthy | 57 | 107 | 10167 |